Loading…
Ernexa Therapeutics Inc. is projected to decline to $5.43 by 2027, a -10% move from its current price of $6.06. ERNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.72 | $6.06 | $6.43 | +0.05% |
| Jul 14 | $5.58 | $6.07 | $6.59 | +0.10% |
| Jul 15 | $5.48 | $6.07 | $6.72 | +0.15% |
| Jul 16 | $5.40 | $6.07 | $6.83 | +0.20% |
| Jul 17 | $5.33 | $6.08 | $6.93 | +0.25% |
| Jul 18 | $5.26 | $6.08 | $7.02 | +0.30% |
| Jul 19 | $5.21 | $6.08 | $7.10 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.21 | $6.08 | $7.10 | +0.35% |
| Week 2 | $4.90 | $6.10 | $7.60 | +0.71% |
| Week 3 | $4.68 | $6.12 | $8.01 | +1.06% |
| Week 4 | $4.51 | $6.15 | $8.38 | +1.42% |
| Week 5 | $4.36 | $6.17 | $8.73 | +1.78% |
| Week 6 | $4.23 | $6.19 | $9.05 | +2.14% |
| Week 7 | $4.12 | $6.21 | $9.37 | +2.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ernexa Therapeutics Inc., a healthcare company in the preclinical stage, develops induced derived mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases. Its lead products are ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. The company has a license agreement with Factor Bioscience Limited and was formerly known as Eterna Therapeutics Inc., changing its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
ERNA is the ticker for Ernexa Therapeutics Inc., a healthcare company currently priced at $5.73 per share, with a market cap of $6.68M and a rank of 5233.
The stock’s near-term technical picture shows bearish sentiment, with a RSI of 40 and key moving averages at SMA50 of $7.73 and SMA200 of $19.30. Price action sits at a support level of $5.73 and faces resistance near $11.66. The 30-day price range spans from $3.82 to $8.58, illustrating a compressed near-term trading window.
Overall, the price outlook through the forecast horizon is mixed but tilts toward eventual upside, with fluctuating yearly averages and defined ranges. The forecast provides a path from modest activity in the mid-2020s toward stronger gains by the mid-to-late-2030s and beyond, culminating in notably higher levels by 2050.
A major floor 68.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 92.4% above — a clean break opens room to run.
A major ceiling 126.8% above — clearing it would confirm fresh momentum.
Key ERNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.07 | Sell | $6.09 | Sell |
| MA 10 | $6.40 | Sell | $6.26 | Sell |
| MA 20 | $6.35 | Sell | $6.62 | Sell |
| MA 50 | $7.78 | Sell | $7.43 | Sell |
| MA 100 | $7.01 | Sell | $10.56 | Sell |
| MA 200 | $19.05 | Sell | $30.50 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.37 | Neutral |
| Stoch RSI (14) | 36.10 | Neutral |
| CCI (20) | -57.77 | Neutral |
| Williams %R (14) | -80.24 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.94 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 19.76 | Buy |
| TRIX (15) | -1.02 | Sell |
| Awesome (5,34) | -1.51 | Sell |
| Ultimate (7,14,28) | 36.50 | Neutral |
| Momentum (10) | -1.34 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 5.76 | Buy |
| ADX (14) | 17.07 | Neutral |
| ATR (14) | 0.39 | Info |
Sentiment: BEARISH. RSI(14): 40. SMA50: $7.73. SMA200: $19.30. Support: $5.73. Resistance: $11.66. 30-Day Range: $3.82 – $8.58.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.74 | $6.06 | $8.12 | 0% | Neutral | |
| $3.94 | $5.43 | $8.10 | -10% | Neutral | |
| $3.06 | $4.48 | $7.12 | -26% | Bearish | |
| $3.29 | $5.08 | $8.47 | -16% | Bearish | |
| $4.05 | $6.54 | $11.36 | +8% | Neutral | |
| $3.92 | $6.62 | $11.90 | +9% | Neutral | |
| $4.16 | $7.33 | $13.58 | +21% | Bullish | |
| $3.65 | $6.71 | $12.77 | +11% | Neutral | |
| $2.86 | $5.46 | $10.65 | -10% | Neutral | |
| $3.25 | $6.46 | $12.90 | +7% | Neutral | |
| $3.38 | $7.52 | $16.51 | +24% | Bullish | |
| $7.44 | $16.53 | $38.02 | +173% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.74 | $6.06 | $7.36 | +0.00% |
| August 2026 | $5.23 | $6.34 | $7.99 | +4.54% |
| September 2026 | $5.16 | $6.34 | $8.17 | +0.14% |
| October 2026 | $4.78 | $5.95 | $7.79 | -6.27% |
| November 2026 | $4.71 | $5.91 | $7.86 | -0.55% |
| December 2026 | $4.75 | $6.03 | $8.12 | +1.97% |
Click any year to see its month-by-month ERNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ERNA is projected to trade between $3.74 and $8.12, averaging $6.06 — a potential gain of 0% from today's $6.06. A consolidation phase looks the most probable path here.
Ernexa Therapeutics Inc.'s 2027 outlook centres on $5.43, within a $3.94 to $8.10 range. That is -10% versus the projected 2026 average. That marks a -10% change versus current levels. Price action looks broadly range-bound.
By 2028, ERNA could reach as high as $7.12, with a base case around $4.48 and support toward $3.06 — roughly -26% from $6.06. Expect choppier, lower action through this leg of the cycle.
Expect ERNA to range from $3.29 to $8.47 through 2029. The $5.08 average target implies a -16% move from current prices. That is up +13% on the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The ERNA price prediction for 2030 points to an average of $6.54 (low $4.05, high $11.36) — a potential gain of +8% on today's $6.06. A consolidation phase looks the most probable path here.
In 2031, ERNA is projected to trade between $3.92 and $11.90, averaging $6.62 — a potential gain of +9% from today's $6.06. That is up +1% on the projected 2030 average. Price action looks broadly range-bound.
Ernexa Therapeutics Inc.'s 2032 outlook centres on $7.33, within a $4.16 to $13.58 range. That is up +11% on the projected 2031 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ERNA could reach as high as $12.77, with a base case around $6.71 and support toward $3.65 — roughly +11% from $6.06. Price action looks broadly range-bound.
Expect ERNA to range from $2.86 to $10.65 through 2034. The $5.46 average target implies a -10% move from current prices. That is -19% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The ERNA price prediction for 2035 points to an average of $6.46 (low $3.25, high $12.90) — a potential gain of +7% on today's $6.06. Price action looks broadly range-bound.
In 2040, ERNA is projected to trade between $3.38 and $16.51, averaging $7.52 — a potential gain of +24% from today's $6.06. That is up +16% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ernexa Therapeutics Inc.'s 2050 outlook centres on $16.53, within a $7.44 to $38.02 range. That is up +120% on the projected 2040 average. That marks a +173% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ERNA today (≈ 165.016502 ERNA) could be worth
$2,727.84
+$1,727.84 (+173%) by 2050 · US Dollar
Based on the average projected ERNA price of $16.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERNAwould be worth at today's price.
$1,000 invested in ERNA on Jul 10, 2025 (≈ 20.20202 ERNA) would be worth
$122.42
-$877.58 (-87.8%) today · 0.12× · US Dollar
Based on a ERNA entry price of $49.5 vs. today's $6.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.27 | $966.51 | -3.3% |
| 1 month ago | $6.34 | $955.84 | -4.4% |
| 3 months ago | $5 | $1,212 | +21.2% |
| 6 months ago | $32.5 | $186.46 | -81.4% |
| 1 year ago | $49.5 | $122.42 | -87.8% |
| All time (5.0y) ago | $89,775 | $0.07 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERNA forecast.
Our base-case forecast reaches $12.00 around 2050.
Implied market cap at $12.00: $14M
The multi-year forecast shows a mixed path with some upside later in the horizon. For 2026, the average price is $5.73 with a range of $3.74 to $7.67 and an ROI of 0% (sentiment NEUTRAL).
In 2027, the average price is $5.09 (range $3.69–$7.59; ROI -11.2%; sentiment NEUTRAL).
In 2028, the average price is $4.29 (range $2.92–$6.81; ROI -25.2%; sentiment BEARISH).
In 2029, the average price is $4.81 (range $3.11–$8.02; ROI -16.1%; sentiment BEARISH).
By 2030, the average price is $6.16 (range $3.81–$10.69; ROI 7.5%; sentiment NEUTRAL). By 2031, the average price is $6.30 (range $3.72–$11.31; ROI 9.9%; sentiment NEUTRAL).
In 2032, the average price is $6.93 (range $3.93–$12.85; ROI 21%; sentiment BULLISH).
In 2033, the average price is $6.32 (range $3.44–$12.03; ROI 10.3%; sentiment NEUTRAL).
In 2034, the average price is $5.18 (range $2.71–$10.11; ROI -9.6%; sentiment NEUTRAL).
In 2035, the average price is $6.11 (range $3.07–$12.20; ROI 6.5%; sentiment NEUTRAL).
In 2040, the average price is $7.17 (range $3.23–$15.74; ROI 25.1%; sentiment BULLISH).
In 2050, the average price is $15.57 (range $7.00–$35.80; ROI 171.7%; sentiment BULLISH).
Overall, the longer-term forecast points to a substantial upside by 2050, though the path includes periods of downside in the late 2020s and early 2030s. These figures are estimates, not guarantees, and reflect varying market conditions implied by the forecast.
Tap a question to reveal the answer.
2030: min $3.81, avg $6.16, max $10.69; ROI 7.5%; sentiment NEUTRAL.
The forecast shows negative ROI in 2027, 2028, 2029, and 2034, while positive ROI appears in 2032 (21%), 2040 (25.1%), and 2050 (171.7%). These are estimates and not guarantees.
2032 max is $12.85, so a price near or above $12 is within the forecast range for that year.
2050: min $7.00, avg $15.57, max $35.80; ROI 171.7%; sentiment BULLISH.
Current price $5.73; market cap $6.68M; rank 5233.
Ernexa Therapeutics Inc. Community Discussion
0Share your Ernexa Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.